Induced pluripotent stem cell-derived natural killer cells gene-modified to express chimeric antigen receptor-targeting solid tumors.
Animals
Antigens, Neoplasm
/ immunology
Clinical Studies as Topic
Combined Modality Therapy
Drug Evaluation, Preclinical
Gene Expression
Genetic Engineering
Humans
Immunotherapy, Adoptive
/ adverse effects
Induced Pluripotent Stem Cells
/ cytology
Killer Cells, Natural
/ cytology
Neoplasms
/ etiology
Prognosis
Receptors, Chimeric Antigen
/ genetics
Treatment Outcome
Chimeric antigen receptor
Immunotherapy
Induced pluripotent stem cell
Natural killer cell
Journal
International journal of hematology
ISSN: 1865-3774
Titre abrégé: Int J Hematol
Pays: Japan
ID NLM: 9111627
Informations de publication
Date de publication:
Nov 2021
Nov 2021
Historique:
received:
14
03
2020
accepted:
14
07
2020
revised:
07
07
2020
pubmed:
25
7
2020
medline:
17
12
2021
entrez:
25
7
2020
Statut:
ppublish
Résumé
The use of allogeneic, pluripotent stem cell-derived immune cells for cancer immunotherapy has been the subject of recent research, including clinical trials. The use of pluripotent stem cells as the source for allogeneic immune cells facilitates stringent quality control of the final product, regarding efficacy, safety, and producibility. In this review, we have described the characteristics of natural killer (NK) cells from multiple cell sources, including pluripotent stem cells, the chimeric antigen receptor (CAR)-modification method and strategy for these NK cells, and the current and planned clinical trials of CAR-modified induced pluripotent stem cell-derived NK cells.
Identifiants
pubmed: 32705572
doi: 10.1007/s12185-020-02951-5
pii: 10.1007/s12185-020-02951-5
doi:
Substances chimiques
Antigens, Neoplasm
0
Receptors, Chimeric Antigen
0
Types de publication
Journal Article
Review
Langues
eng
Sous-ensembles de citation
IM
Pagination
572-579Subventions
Organisme : Japan Agency for Medical Research and Development
ID : Practical Research for Innovative Cancer Control
Informations de copyright
© 2020. Japanese Society of Hematology.
Références
Eshhar Z, Waks T, Gross G, Schindler DG. Specific activation and targeting of cytotoxic lymphocytes through chimeric single chains consisting of antibody-binding domains and the gamma or zeta subunits of the immunoglobulin and T-cell receptors. Proc Natl Acad Sci. 1993;90(2):720–4.
pubmed: 8421711
pmcid: 45737
doi: 10.1073/pnas.90.2.720
Hu Y, Tian ZG, Zhang C. Chimeric antigen receptor (CAR)-transduced natural killer cells in tumor immunotherapy. Acta Pharmacol Sin. 2018;39(2):167–76.
pubmed: 28880014
doi: 10.1038/aps.2017.125
pmcid: 28880014
Klingemann H. Are natural killer cells superior CAR drivers? Oncoimmunology. 2014;3:e28147. https://doi.org/10.4161/onci.28147 .
Vivier E, Nunès JA, Vély F. Natural killer cell signaling pathways. Science. 2004;306(5701):1517–9.
pubmed: 15567854
doi: 10.1126/science.1103478
pmcid: 15567854
Goodridge JP, Önfelt B, Malmberg KJ. Newtonian cell interactions shape natural killer cell education. Immunol Rev. 2015;267(1):197–213.
pubmed: 26284479
pmcid: 4832384
doi: 10.1111/imr.12325
Kärre K. Natural killer cell recognition of missing self. Nat Immunol. 2008;9(5):477–80.
pubmed: 18425103
doi: 10.1038/ni0508-477
pmcid: 18425103
Sun C, Sun H, Zhang C, Tian Z. NK cell receptor imbalance and NK cell dysfunction in HBV infection and hepatocellular carcinoma. Cell Mol Immunol. 2015;12(3):292–302.
pubmed: 25308752
doi: 10.1038/cmi.2014.91
pmcid: 25308752
Miller JS, et al. Successful adoptive transfer and in vivo expansion of human haploidentical NK cells in patients with cancer. Blood. 2005;105(8):3051–7.
pubmed: 15632206
doi: 10.1182/blood-2004-07-2974
pmcid: 15632206
Rubnitz JE, et al. NKAML: a pilot study to determine the safety and feasibility of haploidentical natural killer cell transplantation in childhood acute myeloid leukemia. J Clin Oncol. 2010;28(6):955–9.
pubmed: 20085940
pmcid: 2834435
doi: 10.1200/JCO.2009.24.4590
Shaffer BC, et al. Phase II study of haploidentical natural killer cell infusion for treatment of relapsed or persistent myeloid malignancies following allogeneic hematopoietic cell transplantation. Biol Blood Marrow Transpl. 2016;22(4):705–9.
doi: 10.1016/j.bbmt.2015.12.028
Kalos M, Levine BL, Porter DL, et al. T cells with chimeric antigen receptors have potent antitumor effects and can establish memory in patients with advanced leukemia. Sci Transl Med. 2011;3(95):95ra73. https://doi.org/10.1126/scitranslmed.3002842 .
Maude SL, et al. Chimeric antigen receptor T cells for sustained remissions in leukemia. N Engl J Med. 2014;371(16):1507–17.
pubmed: 4267531
pmcid: 4267531
doi: 10.1056/NEJMoa1407222
Giavridis T, Van Der Stegen SJC, Eyquem J, Hamieh M, Piersigilli A, Sadelain M. CAR T cell-induced cytokine release syndrome is mediated by macrophages and abated by IL-1 blockade letter. Nat Med. 2018;24(6):731–8.
pubmed: 29808005
pmcid: 6410714
doi: 10.1038/s41591-018-0041-7
Rezvani K, Rouce R, Liu E, Shpall E. Engineering natural killer cells for cancer immunotherapy. Mol Ther. 2017;25(8):1769–81.
pubmed: 28668320
pmcid: 5542803
doi: 10.1016/j.ymthe.2017.06.012
Liu E, et al. Use of CAR-transduced natural killer cells in CD19-positive lymphoid tumors. N Engl J Med. 2020;382(6):545–53.
pubmed: 32023374
pmcid: 7101242
doi: 10.1056/NEJMoa1910607
Zhang C, Oberoi P, Oelsner S, et al. Chimeric antigen receptor-engineered NK-92 cells: an off-the-shelf cellular therapeutic for targeted elimination of cancer cells and induction of protective antitumor immunity. Front Immunol. 2017;8:533. https://doi.org/10.3389/fimmu.2017.00533 .
Rotolo R, Leuci V, Donini C, et al. Car-based strategies beyond t lymphocytes: integrative opportunities for cancer adoptive immunotherapy. Int J Mol Sci. 2019;20(11):2839. https://doi.org/10.3390/ijms20112839 .
Herrera L, et al. Adult peripheral blood and umbilical cord blood NK cells are good sources for effective CAR therapy against CD19 positive leukemic cells. Sci Rep. 2019;9(1):1–10.
doi: 10.1038/s41598-019-55239-y
Spanholtz J, Tordoir M, Eissens D, et al. High log-scale expansion of functional human natural killer cells from umbilical cord blood CD34-positive cells for adoptive cancer immunotherapy. PLoS One. 2010;5(2):e9221. https://doi.org/10.1371/journal.pone.0009221 .
Takahashi K, Yamanaka S. Induction of pluripotent stem cells from mouse embryonic and adult fibroblast cultures by defined factors. Cell. 2006;126:663–76.
doi: 10.1016/j.cell.2006.07.024
Takahashi K, et al. Induction of pluripotent stem cells from adult human fibroblasts by defined factors. Cell. 2007;131(5):861–72.
pubmed: 18035408
pmcid: 18035408
doi: 10.1016/j.cell.2007.11.019
Yu J, Vodyanik MA, Smuga-Otto K, Antosiewicz-Bourget J, Frane JL, Tian S, Nie J, Jonsdottir GA, Ruotti V, Stewart R, Slukvin II. Induced pluripotent stem cell lines derived from human somatic cells. Science. 2007;318(21):1917–20.
pubmed: 18029452
doi: 10.1126/science.1151526
pmcid: 18029452
Ghosh Z, Wilson KD, Wu Y, Hu S, Quertermous T, Wu JC. Persistent donor cell gene expression among human induced pluripotent stem cells contributes to differences with human embryonic stem cells. PLoS One. 2010;5(2):e8975. https://doi.org/10.1371/journal.pone.0008975 .
Marchetto MCN, Yeo GW, Kainohana O, Marsala M, Gage FH, Muotri AR. Transcriptional signature and memory retention of human-induced pluripotent stem cells. PLoS One. 2009;4(9):e7076. https://doi.org/10.1371/journal.pone.0007076 .
Valamehr B, et al. Platform for induction and maintenance of transgene-free hiPSCs resembling ground state pluripotent stem cells. Stem Cell Rep. 2014;2(3):366–81.
doi: 10.1016/j.stemcr.2014.01.014
Knorr DA. Clinical-scale derivation of natural killer cells from human pluripotent stem cells for cancer therapy. Stem Cells Transl Med. 2013;2(4):274–83.
pubmed: 23515118
pmcid: 3659832
doi: 10.5966/sctm.2012-0084
Woll PS, Martin CH, Miller JS, Kaufman DS. Human embryonic stem cell-derived NK cells acquire functional receptors and cytolytic activity. J Immunol. 2005;175(8):5095–103.
pubmed: 16210613
doi: 10.4049/jimmunol.175.8.5095
pmcid: 16210613
Woll PS, et al. Human embryonic stem cells differentiate into a homogeneous population of natural killer cells with potent in vivo antitumor activity. Blood. 2009;113(24):6094–101.
pubmed: 19365083
pmcid: 2699231
doi: 10.1182/blood-2008-06-165225
Taylor CJ, Bolton EM, Pocock S, Sharples LD, Pedersen RA, Bradley JA. Banking on human embryonic stem cells: estimating the number of donor cell lines needed for HLA matching. Lancet. 2005;366(9502):2019–25.
pubmed: 16338451
doi: 10.1016/S0140-6736(05)67813-0
pmcid: 16338451
Nakatsuji N, Nakajima F, Tokunaga K. HLA-haplotype banking and iPS cells. Nat Biotechnol. 2008;26(7):739–40.
pubmed: 18612291
doi: 10.1038/nbt0708-739
pmcid: 18612291
Hirata RK, et al. HLA-E-expressing pluripotent stem cells escape allogeneic responses and lysis by NK cells. Nat Biotechnol. 2017;35(8):765–72.
pubmed: 28504668
pmcid: 5548598
doi: 10.1038/nbt.3860
Fauriat C, et al. Estimation of the size of the alloreactive NK cell repertoire: studies in individuals homozygous for the group A KIR haplotype. J. Immunol. 2008;181(9):6010–9.
pubmed: 18941190
doi: 10.4049/jimmunol.181.9.6010
pmcid: 18941190
Nguyen S, et al. HLA-E upregulation on IFN-γ-activated AML blasts impairs CD94/NKG2A-dependent NK cytolysis after haplo-mismatched hematopoietic SCT. Bone Marrow Transpl. 2009;43(9):693–9.
doi: 10.1038/bmt.2008.380
André P, et al. Anti-NKG2A mAb is a checkpoint inhibitor that promotes anti-tumor immunity by unleashing both T and NK cells. Cell. 2018;175(7):1731.e13–1743.e13.
doi: 10.1016/j.cell.2018.10.014
Björkström NK, et al. Expression patterns of NKG2A, KIR, and CD57 define a process of CD56 dim NK-cell differentiation uncoupled from NK-cell education. Blood. 2010;116(19):3853–64.
pubmed: 20696944
doi: 10.1182/blood-2010-04-281675
pmcid: 20696944
Zeng J, Tang SY, Toh LL, Wang S. Generation of ‘off-the-shelf’ natural killer cells from peripheral blood cell-derived induced pluripotent stem cells. Stem Cell Rep. 2017;9(6):1796–812.
doi: 10.1016/j.stemcr.2017.10.020
Hermanson DL, et al. Induced pluripotent stem cell-derived natural killer cells for treatment of ovarian cancer. Stem Cells. 2016;34(1):93–101.
pubmed: 26503833
doi: 10.1002/stem.2230
pmcid: 26503833
Béziat V, et al. Influence of KIR gene copy number on natural killer cell education. Blood. 2013;121(23):4703–7.
pubmed: 23637128
pmcid: 3674669
doi: 10.1182/blood-2012-10-461442
Béziat V, et al. Tracing dynamic expansion of human NK-cell subsets by high-resolution analysis of KIR repertoires and cellular differentiation. Eur J Immunol. 2014;44(7):2192–6.
pubmed: 24723455
pmcid: 4282447
doi: 10.1002/eji.201444464
Liu E, et al. Cord blood NK cells engineered to express IL-15 and a CD19-targeted CAR show long-term persistence and potent antitumor activity. Leukemia. 2018;32(2):520–31.
pubmed: 28725044
doi: 10.1038/leu.2017.226
pmcid: 28725044
Li Y, Hermanson DL, Moriarity BS, Kaufman DS. Human iPSC-derived natural killer cells engineered with chimeric antigen receptors enhance anti-tumor activity. Cell Stem Cell. 2018;23(2):181.e5–192.e5.
Ueda T, et al. Non-clinical efficacy, safety, and stable clinical cell processing of iPSC- derived anti-GPC3 CAR-expressing NK/ILC cells. Cancer Sci. 2020.
Ueda T, Kumagai A, Iriguchi S, et al. Non-clinical efficacy, safety and stable clinical cell processing of induced pluripotent stem cell-derived anti-glypican-3 chimeric antigen receptor-expressing natural killer/innate lymphoid cells. Cancer Sci. 2020;111(5):1478–1490. https://doi.org/10.1111/cas.14374 .
D'Aloia MM, Zizzari IG, Sacchetti B, Pierelli L, Alimandi M. CAR-T cells: the long and winding road to solid tumors. Cell Death Dis. 2018;9(3):282. https://doi.org/10.1038/s41419-018-0278-6
Sampson JH, Archer GE, Mitchell DA, Heimberger AB, Bigner DD. Tumor-specific immunotherapy targeting the EGFRvIII mutation in patients with malignant glioma. Semin Immunol. 2008;20(5):267–75.
pubmed: 18539480
pmcid: 2633865
doi: 10.1016/j.smim.2008.04.001
Ghiringhelli F, et al. CD4 + CD25 + regulatory T cells inhibit natural killer cell functions in a transforming growth factor-β-dependent manner. J Exp Med. 2005;202(8):1075–85.
pubmed: 16230475
pmcid: 2213209
doi: 10.1084/jem.20051511
Waldmann TA, Dubois S, Tagaya Y. Contrasting roles of IL-2 and IL-15 in the life and death of lymphocytes: implications for immunotherapy. Immunity. 2001;14(2):105–10.
pubmed: 11239443
pmcid: 11239443
Fehniger TA, Caligiuri MA. Interleukin 15: biology and relevance to human disease. Blood. 2001;97(1):14–32.
pubmed: 11133738
doi: 10.1182/blood.V97.1.14
pmcid: 11133738
Wrangle JM, et al. ALT-803, an IL-15 superagonist, in combination with nivolumab in patients with metastatic non-small cell lung cancer: a non-randomised, open-label, phase 1b trial. Lancet Oncol. 2018;19(5):694–704.
pubmed: 29628312
pmcid: 6089612
doi: 10.1016/S1470-2045(18)30148-7
Romee R, et al. First-in-human phase 1 clinical study of the IL-15 superagonist complex ALT-803 to treat relapse after transplantation. Blood. 2018;131(23):2515–27.
pubmed: 29463563
pmcid: 5992862
doi: 10.1182/blood-2017-12-823757
Beider K, et al. Involvement of CXCR4 and IL-2 in the homing and retention of human NK and NK T cells to the bone marrow and spleen of NOD/SCID mice. Blood. 2003;102(6):1951–8.
pubmed: 12730102
doi: 10.1182/blood-2002-10-3293
pmcid: 12730102
Groth A, Klöss S, Pogge Von Strandmann E, Koehl U, Koch J. Mechanisms of tumor and viral immune escape from natural killer cell-mediated surveillance. J Innate Immun. 2011;3(4):344–54.
pubmed: 21576922
doi: 10.1159/000327014
pmcid: 21576922
Fisher B, et al. Tumor localization of adoptively transferred indium-111 labeled tumor infiltrating lymphocytes in patients with metastatic melanoma. J Clin Oncol. 1989;7(2):250–61.
pubmed: 2644399
doi: 10.1200/JCO.1989.7.2.250
pmcid: 2644399
Pockaj BA, et al. Localization of 111Indium-labeled tumor infiltrating lymphocytes to tumor in patients receiving adoptive immunotherapy. Augmentation with cyclophosphamide and correlation with response. Cancer. 1994;73(6):1731–7.
pubmed: 8156501
doi: 10.1002/1097-0142(19940315)73:6<1731::AID-CNCR2820730630>3.0.CO;2-H
pmcid: 8156501
Paul S, Lal G. The molecular mechanism of natural killer cells function and its importance in cancer immunotherapy. Front Immunol. 2017;8.
Paul S, Lal G. The Molecular Mechanism of Natural Killer Cells Function and Its Importance in Cancer Immunotherapy. Front Immunol. 2017;8:1124. https://doi.org/10.3389/fimmu.2017.01124
Melero I, Rouzaut A, Motz GT, Coukos G. T-cell and NK-cell infiltration into solid tumors: a key limiting factor for efficacious cancer immunotherapy. Cancer Discov. 2014;4(5):522–6.
pubmed: 24795012
pmcid: 4142435
doi: 10.1158/2159-8290.CD-13-0985
Wennerberg E, Kremer V, Childs R, Lundqvist A. CXCL10-induced migration of adoptively transferred human natural killer cells toward solid tumors causes regression of tumor growth in vivo. Cancer Immunol Immunother. 2014;64(2):225–35.
pubmed: 25344904
doi: 10.1007/s00262-014-1629-5
pmcid: 25344904
Mikucki ME, et al. Non-redundant requirement for CXCR3 signalling during tumoricidal T-cell trafficking across tumour vascular checkpoints. Nat Commun. 2015;6.
Mikucki ME, Fisher DT, Matsuzaki J, et al. Non-redundant requirement for CXCR3 signalling during tumoricidal T-cell trafficking across tumour vascular checkpoints. Nat Commun. 2015;6:7458. https://doi.org/10.1038/ncomms8458 .
Nishio N, et al. Armed oncolytic virus enhances immune functions of chimeric antigen receptor-modified T cells in solid tumors. Cancer Res. 2014;74(18):5195–205.
pubmed: 25060519
pmcid: 4167556
doi: 10.1158/0008-5472.CAN-14-0697
Whilding LM, Vallath S, Maher J. The integrin αvβ6: a novel target for CAR T-cell immunotherapy? Biochem Soc Trans. 2016;44(2):349–55.
pubmed: 27068939
doi: 10.1042/BST20150249
pmcid: 27068939
Wang W, et al. Specificity redirection by CAR with human VEGFR-1 affinity endows T lymphocytes with tumor-killing ability and anti-angiogenic potency. Gene Ther. 2013;20(10):970–8.
pubmed: 23636245
doi: 10.1038/gt.2013.19
pmcid: 23636245
Stewart MD, Sanderson RD. Heparan sulfate in the nucleus and its control of cellular functions. Matrix Biol. 2014;35:56–9.
pubmed: 24309018
doi: 10.1016/j.matbio.2013.10.009
pmcid: 24309018
Speiser DE, Ho PC, Verdeil G. Regulatory circuits of T cell function in cancer. Nat Rev Immunol. 2016;16(10):599–611.
pubmed: 27526640
doi: 10.1038/nri.2016.80
pmcid: 27526640
Mao Y, et al. A new effect of IL-4 on human γδ cells: promoting regulatory Vδ1 T cells via IL-10 production and inhibiting function of Vδ2 T cells. Cell Mol Immunol. 2016;13(2):217–28.
pubmed: 25942601
doi: 10.1038/cmi.2015.07
pmcid: 25942601
Krneta T, Gillgrass A, Chew M, Ashkar AA. The breast tumor microenvironment alters the phenotype and function of natural killer cells. Cell Mol Immunol. 2016;13(5):628–39.
pubmed: 26277898
doi: 10.1038/cmi.2015.42
pmcid: 26277898
Rekik R, Belhadj Hmida N, Ben Hmid A, Zamali I, Kammoun N, Ben Ahmed M. PD-1 induction through TCR activation is partially regulated by endogenous TGF-β. Cell Mol Immunol. 2015;12(5):648–9.
pubmed: 25363526
doi: 10.1038/cmi.2014.104
pmcid: 25363526
Zhang S, et al. Analysis of CD8 + Treg cells in patients with ovarian cancer: a possible mechanism for immune impairment. Cell Mol Immunol. 2015;12(5):580–91.
pubmed: 26166762
pmcid: 4579658
doi: 10.1038/cmi.2015.57
Mohammed S, et al. Improving chimeric antigen receptor-modified T cell function by reversing the immunosuppressive tumor microenvironment of pancreatic cancer. Mol Ther. 2017;25(1):249–58.
pubmed: 28129119
pmcid: 5363304
doi: 10.1016/j.ymthe.2016.10.016